Cystic Fibrosis Related Diabetes
12
0
0
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
8.3%
1 terminated out of 12 trials
87.5%
+1.0% vs benchmark
8%
1 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (12)
Genetic Modifiers of Cystic Fibrosis Related Diabetes
Investigating the Relationship Between Glycemia and Sleep in Adults With Cystic Fibrosis-Related Diabetes
Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)
Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes
Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.
Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)
Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)
Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis
The Use of Home Oral Glucose Tolerance Test Kit in Screening Cystic Fibrosis Related Diabetes
Effects of an Exercise Program Among CF Patients With Dysglycemia
The Microvascular Complications Study
Insulin Glargine Vs Standard Insulin Therapy